Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Figure 3 Subgroup analysis of progression-free survival and overall survival stratified by clinical factors. A: Less than 65 years old; B: Primary lesion of the right-sided colon; C: BRAF mutations; D: Less than three sites of metastatic disease; E: Without lung metastases; F: With liver metastases; G: The Eastern cooperative oncology group score of 0-1. ^aP<0.05, and the difference is statistically significant. F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.